Literature DB >> 9144358

Detection of HLA class I-specific antibodies by the QuikScreen enzyme-linked immunosorbent assay.

D P Lucas1, M L Paparounis, L Myers, J M Hart, A A Zachary.   

Abstract

The GTI QuikScreen test is an enzyme-linked immunosorbent assay (ELISA) that uses soluble HLA class I antigens as targets. In tests of 5,893 human serum specimens, we evaluated the reliability, sensitivity, and utility of the GTI QuikScreen test for detecting HLA class I-specific antibody. We found that the test could reliably detect HLA-specific antibodies of the immunoglobulin G (IgG) but not the IgM class. The degree of correlation with lymphocytotoxicity testing varied among the different serum sources, with the best correlation achieved with sera from renal transplant candidates (r > 0.7) and the poorest with sera from patients with end-stage liver disease (r = 0.26), possibly because of elevated alkaline phosphatase levels in the liver patients. Test reproducibility was high (96%), and test failure rate was low (1.7%). The test sensitivity is comparable to that of the antiglobulin cytotoxicity and, possibly, even flow cytometric tests. There was a highly significant (P < 0.001) correlation between the optical densities obtained in the ELISA and the percent panel reactive antibody determined by cytotoxicity testing. Therefore, although designed only to determine the presence or absence of HLA-specific antibody, GTI QuikScreen test results also provided an indication of the extent of sensitization. The test is one of the most effective and efficient ways to determine if antibodies producing a positive result in crossmatch tests are specific for HLA class I antigens. As an adjunct to serum screening by cytotoxicity testing, the GTI QuikScreen test can produce a substantial savings of time and effort that reduces the cost to the laboratory and to the patient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144358      PMCID: PMC170513          DOI: 10.1128/cdli.4.3.252-257.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  10 in total

1.  Quantification of soluble HLA class I gene products by an enzyme linked immunosorbent assay.

Authors:  I Doxiadis; U Westhoff; H Grosse-Wilde
Journal:  Blut       Date:  1989-11

2.  Calculation of a predictive value for transplantation.

Authors:  A A Zachary; W E Braun
Journal:  Transplantation       Date:  1985-03       Impact factor: 4.939

Review 3.  Flow cytometry in the transplant laboratory.

Authors:  R A Bray
Journal:  Ann N Y Acad Sci       Date:  1993-03-20       Impact factor: 5.691

4.  A rapid flow cytometry assay for HLA antibody detection using a pooled cell panel covering 14 serological crossreacting groups.

Authors:  T W Shroyer; M H Deierhoi; C A Mink; L R Cagle; S L Hudson; S D Rhea; A G Diethelm
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

5.  Typing of a panel of soluble HLA class I antigens by enzyme-linked immunosorbent assay.

Authors:  C Pouletty; I Mercier; L Glanville; N Tomavo; L Igoudin; P Pouletty; R Buelow
Journal:  Hum Immunol       Date:  1994-07       Impact factor: 2.850

Review 6.  Monitoring HLA alloimmunization. Analysis of HLA alloantibodies in the serum of prospective transplant recipients.

Authors:  T C Fuller
Journal:  Clin Lab Med       Date:  1991-09       Impact factor: 1.935

7.  The frequencies of HLA alleles and haplotypes and their distribution among donors and renal patients in the UNOS registry.

Authors:  A A Zachary; A G Steinberg; W B Bias; M S Leffell
Journal:  Transplantation       Date:  1996-07-27       Impact factor: 4.939

8.  HLA--C antigens on platelets.

Authors:  G Mueller-Eckhardt; M Hauck; W Kayser; C Mueller-Eckhardt
Journal:  Tissue Antigens       Date:  1980-07

9.  Enzyme-linked immunoassay for anti-HLA antibodies--an alternative to panel studies by lymphocytotoxicity.

Authors:  K J Kao; J C Scornik; S J Small
Journal:  Transplantation       Date:  1993-01       Impact factor: 4.939

10.  Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients.

Authors:  G E Rodey; J F Neylan; J D Whelchel; K W Revels; R A Bray
Journal:  Hum Immunol       Date:  1994-04       Impact factor: 2.850

  10 in total
  5 in total

Review 1.  Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes.

Authors:  Gerald Schlaf; Beatrix Pollok-Kopp; Wolfgang W Altermann
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia.

Authors:  Julie A Peterson; Stephanie M Balthazor; Brian R Curtis; Janice G McFarland; Richard H Aster
Journal:  Transfusion       Date:  2005-09       Impact factor: 3.157

3.  Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure.

Authors:  Michael J Casey; Xuerong Wen; Liise K Kayler; Ravi Aiyer; Juan C Scornik; Herwig-Ulf Meier-Kriesche
Journal:  Transplantation       Date:  2014-08-15       Impact factor: 4.939

4.  Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching.

Authors:  Gerald Schlaf; Beatrix Pollok-Kopp; Till Manzke; Oliver Schurat; Wolfgang Altermann
Journal:  NDT Plus       Date:  2010-09-15

Review 5.  Detection of HLA Antibodies in Organ Transplant Recipients - Triumphs and Challenges of the Solid Phase Bead Assay.

Authors:  Brian D Tait
Journal:  Front Immunol       Date:  2016-12-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.